Cardea Bio Announces a Collaboration Agreement With Siemens Healthineers

Cardea Bio, Inc. - the world's only mass producer of biocompatible semiconductors - announced a collaboration agreement with Siemens Healthineers' Center for Innovation in Diagnostics (CID) to assess feasibility of developing real-time biosensor applications using Cardea's BPU™ (Biosignal Processing Unit) Platform.

CEO of Cardea, Michael Heltzen, adds, "We're very humbled and proud that Siemens Healthineers has identified the transformational capabilities that our BPU™ Platform can bring to several areas across their existing and future product portfolios, and we look forward to the opportunity of realizing the potential of our technology together with the impressive team at Siemens Healthineers that has product development and marketing capabilities like few others in the world."

Cardea is a Serra Capital II and Serra Capital II Follow-on-Fund company.

To view the entire article, follow here.